5 French stocks that may have been penalized too harshly according to Barclays By Investing.com
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 18 2024
0mins
Should l Buy SNY?
Source: Investing.com
- French Stocks Rebound: French stocks bounced back after significant losses last week, with the CAC 40 closing up 0.91% on Monday.
- Buying Opportunities: Barclays analysts suggest that the current situation could present buying opportunities for investors.
- Uncertain Legislative Elections: Polls indicate uncertain outcomes for legislative elections, leading to erratic price movements in the stock market.
- Main Risks for Investors: Barclays highlighted main risks concerning investors amid the current political uncertainty.
- Stock Recommendations: Barclays provided ratings and price targets for various stocks, including BNP Paribas, Edenred, Veolia Environnement SA ADR, Vinci SA, and Sanofi. They also mentioned telecom operators Orange SA ADR and Bouygues as more vulnerable due to exposure to the French domestic market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNY
Wall Street analysts forecast SNY stock price to rise
5 Analyst Rating
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 47.720
Low
57.00
Averages
79.36
High
119.07
Current: 47.720
Low
57.00
Averages
79.36
High
119.07
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trump Nominates Erica Schwartz as CDC Director
- New CDC Director Nomination: President Trump has nominated Erica Schwartz to lead the Centers for Disease Control and Prevention (CDC), ending a months-long search for a permanent director, with her confirmation pending in the Senate, which could influence the agency's policy direction.
- Health Policy Changes: Schwartz will take over amid controversial health policy changes overseen by Health and Human Services Secretary Robert F. Kennedy Jr., including a comprehensive overhaul of childhood vaccine recommendations, directly impacting public health strategies.
- Extensive Medical Background: Having served as deputy surgeon general during the Trump administration and playing a key role in the U.S. response to the COVID-19 pandemic, Schwartz brings over 20 years of military experience, including as the Coast Guard's chief medical officer, providing strong credentials for her new role.
- Transition from Acting Director: Prior to Schwartz's nomination, Jay Bhattacharya served as acting CDC director, but his term expired last month under federal law, leaving the CDC without a Senate-confirmed leader for months, and Schwartz's appointment is expected to bring new leadership to the agency.
See More
Taiho Ventures Celebrates 10th Anniversary with Strong Track Record
- Leading Investment Scale: Taiho Ventures maintains the largest fund size among Japanese pharmaceutical CVCs, focusing on supporting innovative therapeutics startups and leveraging its R&D and business management expertise to drive the societal application of cutting-edge technologies and therapies.
- Successful Investment Cases: Over the past decade, Taiho Ventures has invested in more than 30 innovative companies developing novel therapeutics and cutting-edge healthcare technologies, achieving multiple successful exits, including Dren Bio acquired by Sanofi and Halda Therapeutics acquired by Johnson & Johnson.
- Strengthening R&D Pipeline: Taiho Ventures' first portfolio company, Arcus Biosciences, granted Taiho Pharmaceutical exclusive licenses to five pipeline programs, significantly enhancing Taiho Pharmaceutical's R&D pipeline and advancing its strategic positioning in oncology.
- Global Investment Commitment: Taiho Ventures actively invests across the U.S., Europe, and Japan, utilizing an evergreen fund structure to ensure long-term investment support, and is dedicated to collaborating closely with entrepreneurs and innovators to advance transformative healthcare technologies that address unmet medical needs.
See More
Dupixent Approved by EU for Pediatric CSU Treatment
- Approval Expansion: The European Commission has approved Dupixent (Dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in children aged 2 to 11 years, marking a significant expansion of the drug's indications to address the urgent needs of children unresponsive to antihistamines.
- Clinical Trial Support: This approval is based on data from the LIBERTY-CUPID clinical trial program, which demonstrated that Dupixent significantly reduced urticaria activity in adults, further validating its efficacy and safety in the pediatric population.
- Global Market Performance: Dupixent has received regulatory approvals in over 60 countries, with Sanofi reporting global net sales of $17.8 billion for 2025, a significant increase from the previous year, indicating strong market demand and potential for the drug.
- Market Reaction: Despite the positive approval news, Sanofi's stock fell 0.68% in Friday's trading and continued to decline by 0.97% in pre-market trading, reflecting a cautious market sentiment towards the biopharmaceutical sector.
See More
European Commission Approves DPREMIUM
- Drug Approval: Regeneron and Sanofi announced that the European Commission has approved their new drug DPREMIUM, which will support their competitiveness in the European market and is expected to drive sales growth.
- Market Potential: The approval of DPREMIUM means the companies can meet the increasing patient demand in Europe, thereby enhancing their market share in the biopharmaceutical sector, particularly in treating specific diseases.
- Strategic Partnership: This approval further solidifies the collaboration between Regeneron and Sanofi, as both companies will jointly promote DPREMIUM, which is expected to accelerate the product's market launch.
- Future Outlook: With the launch of DPREMIUM, Regeneron and Sanofi anticipate a new revenue stream, strengthening their position in the global pharmaceutical market, especially in the highly competitive biopharmaceutical industry.
See More
Dupixent Approved in EU for Children with CSU
- Pediatric Indication Expansion: Dupixent has been approved in the EU for treating moderate-to-severe chronic spontaneous urticaria (CSU) in children aged 2 to 11, based on data from the LIBERTY-CUPID clinical trial, which demonstrated significant efficacy in adults, indicating potential effectiveness in children.
- Diverse Indications: This approval expands Dupixent's indications in the EU to include four chronic diseases driven by type 2 inflammation, further solidifying its market position among pediatric populations and is expected to drive future sales growth.
- U.S. Application Progress: The supplemental Biologics License Application (sBLA) for Dupixent has been accepted for review in the U.S. for children aged 2 to 11 with CSU, showcasing the company's strategic intent for global expansion and potentially supporting future revenue growth.
- Optimistic Market Outlook: With approvals in multiple countries, Sanofi and Regeneron are poised to benefit from the expansion into the pediatric market, enhancing their competitiveness in chronic disease treatment and likely having a positive impact on financial performance.
See More
Dupixent Approved by EU for Pediatric CSU Treatment
- Indication Expansion: Regeneron and Sanofi announced that Dupixent has been approved by the European Commission for treating moderate-to-severe chronic spontaneous urticaria in children aged 2 to 11 years, addressing a significant treatment gap for patients with inadequate response to antihistamines.
- Clinical Trial Support: The approval is based on data from the LIBERTY-CUPID clinical program, which includes efficacy results from two Phase 3 studies in adults and pharmacokinetic, safety, and efficacy data from the CUPIDKids Phase 3 trial in children, demonstrating Dupixent's broad applicability.
- Significant Efficacy: Results showed that Dupixent significantly reduced overall urticaria activity, including itch and hive severity, compared to placebo over 24 weeks, indicating its effectiveness in managing symptoms.
- Increased Patient Benefit: The proportion of patients achieving well-controlled disease and complete response was significantly higher in the Dupixent group compared to placebo, highlighting the potential clinical value of the drug in the pediatric population.
See More
Trump Nominates Erica Schwartz as CDC Director
- New CDC Director Nomination: President Trump has nominated Erica Schwartz to lead the Centers for Disease Control and Prevention (CDC), ending a months-long search for a permanent director, with her confirmation pending in the Senate, which could influence the agency's policy direction.
- Health Policy Changes: Schwartz will take over amid controversial health policy changes overseen by Health and Human Services Secretary Robert F. Kennedy Jr., including a comprehensive overhaul of childhood vaccine recommendations, directly impacting public health strategies.
- Extensive Medical Background: Having served as deputy surgeon general during the Trump administration and playing a key role in the U.S. response to the COVID-19 pandemic, Schwartz brings over 20 years of military experience, including as the Coast Guard's chief medical officer, providing strong credentials for her new role.
- Transition from Acting Director: Prior to Schwartz's nomination, Jay Bhattacharya served as acting CDC director, but his term expired last month under federal law, leaving the CDC without a Senate-confirmed leader for months, and Schwartz's appointment is expected to bring new leadership to the agency.
See More
Taiho Ventures Celebrates 10th Anniversary with Strong Track Record
- Leading Investment Scale: Taiho Ventures maintains the largest fund size among Japanese pharmaceutical CVCs, focusing on supporting innovative therapeutics startups and leveraging its R&D and business management expertise to drive the societal application of cutting-edge technologies and therapies.
- Successful Investment Cases: Over the past decade, Taiho Ventures has invested in more than 30 innovative companies developing novel therapeutics and cutting-edge healthcare technologies, achieving multiple successful exits, including Dren Bio acquired by Sanofi and Halda Therapeutics acquired by Johnson & Johnson.
- Strengthening R&D Pipeline: Taiho Ventures' first portfolio company, Arcus Biosciences, granted Taiho Pharmaceutical exclusive licenses to five pipeline programs, significantly enhancing Taiho Pharmaceutical's R&D pipeline and advancing its strategic positioning in oncology.
- Global Investment Commitment: Taiho Ventures actively invests across the U.S., Europe, and Japan, utilizing an evergreen fund structure to ensure long-term investment support, and is dedicated to collaborating closely with entrepreneurs and innovators to advance transformative healthcare technologies that address unmet medical needs.
See More
Dupixent Approved by EU for Pediatric CSU Treatment
- Approval Expansion: The European Commission has approved Dupixent (Dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in children aged 2 to 11 years, marking a significant expansion of the drug's indications to address the urgent needs of children unresponsive to antihistamines.
- Clinical Trial Support: This approval is based on data from the LIBERTY-CUPID clinical trial program, which demonstrated that Dupixent significantly reduced urticaria activity in adults, further validating its efficacy and safety in the pediatric population.
- Global Market Performance: Dupixent has received regulatory approvals in over 60 countries, with Sanofi reporting global net sales of $17.8 billion for 2025, a significant increase from the previous year, indicating strong market demand and potential for the drug.
- Market Reaction: Despite the positive approval news, Sanofi's stock fell 0.68% in Friday's trading and continued to decline by 0.97% in pre-market trading, reflecting a cautious market sentiment towards the biopharmaceutical sector.
See More
European Commission Approves DPREMIUM
- Drug Approval: Regeneron and Sanofi announced that the European Commission has approved their new drug DPREMIUM, which will support their competitiveness in the European market and is expected to drive sales growth.
- Market Potential: The approval of DPREMIUM means the companies can meet the increasing patient demand in Europe, thereby enhancing their market share in the biopharmaceutical sector, particularly in treating specific diseases.
- Strategic Partnership: This approval further solidifies the collaboration between Regeneron and Sanofi, as both companies will jointly promote DPREMIUM, which is expected to accelerate the product's market launch.
- Future Outlook: With the launch of DPREMIUM, Regeneron and Sanofi anticipate a new revenue stream, strengthening their position in the global pharmaceutical market, especially in the highly competitive biopharmaceutical industry.
See More
Dupixent Approved in EU for Children with CSU
- Pediatric Indication Expansion: Dupixent has been approved in the EU for treating moderate-to-severe chronic spontaneous urticaria (CSU) in children aged 2 to 11, based on data from the LIBERTY-CUPID clinical trial, which demonstrated significant efficacy in adults, indicating potential effectiveness in children.
- Diverse Indications: This approval expands Dupixent's indications in the EU to include four chronic diseases driven by type 2 inflammation, further solidifying its market position among pediatric populations and is expected to drive future sales growth.
- U.S. Application Progress: The supplemental Biologics License Application (sBLA) for Dupixent has been accepted for review in the U.S. for children aged 2 to 11 with CSU, showcasing the company's strategic intent for global expansion and potentially supporting future revenue growth.
- Optimistic Market Outlook: With approvals in multiple countries, Sanofi and Regeneron are poised to benefit from the expansion into the pediatric market, enhancing their competitiveness in chronic disease treatment and likely having a positive impact on financial performance.
See More
Dupixent Approved by EU for Pediatric CSU Treatment
- Indication Expansion: Regeneron and Sanofi announced that Dupixent has been approved by the European Commission for treating moderate-to-severe chronic spontaneous urticaria in children aged 2 to 11 years, addressing a significant treatment gap for patients with inadequate response to antihistamines.
- Clinical Trial Support: The approval is based on data from the LIBERTY-CUPID clinical program, which includes efficacy results from two Phase 3 studies in adults and pharmacokinetic, safety, and efficacy data from the CUPIDKids Phase 3 trial in children, demonstrating Dupixent's broad applicability.
- Significant Efficacy: Results showed that Dupixent significantly reduced overall urticaria activity, including itch and hive severity, compared to placebo over 24 weeks, indicating its effectiveness in managing symptoms.
- Increased Patient Benefit: The proportion of patients achieving well-controlled disease and complete response was significantly higher in the Dupixent group compared to placebo, highlighting the potential clinical value of the drug in the pediatric population.
See More
